Susan J. Lucas

Array ( [id] => 13574897 [patent_doc_number] => 20180338997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS [patent_app_type] => utility [patent_app_number] => 15/829160 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12409236 [patent_doc_number] => 09970012 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer [patent_app_type] => utility [patent_app_number] => 15/817632 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 52 [patent_no_of_words] => 26336 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15817632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12729646 [patent_doc_number] => 20180135049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => RNAI INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS [patent_app_type] => utility [patent_app_number] => 15/813469 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13329155 [patent_doc_number] => 20180216115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => Compositions and Methods for Inhibiting Expression of the PCSK9 Gene [patent_app_type] => utility [patent_app_number] => 15/807275 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15807275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12206064 [patent_doc_number] => 20180051290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease' [patent_app_type] => utility [patent_app_number] => 15/803579 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11428 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681952 [patent_doc_number] => 20180119150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => Methods for Treating Acute Myeloid Leukemia and Nanoparticle Complexes of miR-22 Utilized Therein [patent_app_type] => utility [patent_app_number] => 15/803190 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051772 [patent_doc_number] => 11525145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => SynP198, a promoter for the specific expression of genes in direction selective retinal ganglion cells [patent_app_type] => utility [patent_app_number] => 16/346680 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8926 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12624960 [patent_doc_number] => 20180100150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-12 [patent_title] => Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/800517 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 888 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12637590 [patent_doc_number] => 20180104360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Protein Reduction [patent_app_type] => utility [patent_app_number] => 15/787405 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -97 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15787405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960473 [patent_doc_number] => 20200163988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of IDO [patent_app_type] => utility [patent_app_number] => 16/340292 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15455021 [patent_doc_number] => 20200040335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => IMPROVEMENTS IN OR RELATING TO GENE SILENCING [patent_app_type] => utility [patent_app_number] => 16/339989 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357851 [patent_doc_number] => 20180230465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/709325 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15709325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300783 [patent_doc_number] => 20180201928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => MICROMIRS [patent_app_type] => utility [patent_app_number] => 15/705739 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963657 [patent_doc_number] => 20190309307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/333133 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178952 [patent_doc_number] => 20180037889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHODS OF TREATING DYSTROPHIES' [patent_app_type] => utility [patent_app_number] => 15/698406 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 17416 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15698406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885431 [patent_doc_number] => 10195247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration [patent_app_type] => utility [patent_app_number] => 15/696993 [patent_app_country] => US [patent_app_date] => 2017-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 109 [patent_no_of_words] => 22348 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15696993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14535179 [patent_doc_number] => 20190203211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => TREATMENT AND PREVENTION OF VIRAL INFECTION [patent_app_type] => utility [patent_app_number] => 16/330604 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138495 [patent_doc_number] => 20180016579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS' [patent_app_type] => utility [patent_app_number] => 15/692669 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6843 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15692669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717855 [patent_doc_number] => 20170369882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => FULLY STABILIZED ASYMMETRIC SIRNA [patent_app_type] => utility [patent_app_number] => 15/691120 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15691120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17103171 [patent_doc_number] => 11123361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Double-stranded oligo RNA structure comprising miRNA [patent_app_type] => utility [patent_app_number] => 16/302670 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 10 [patent_no_of_words] => 10250 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302670 [rel_patent_id] =>[rel_patent_doc_number] =>)